REUTERS: Retrophin Inc said on Thursday it was discontinuing the late-stage study for its rare neurological disorder treatment after it failed to improve patients' ability to conduct daily activities such as eating and walking, sending shares down 30per cent.
The treatment, fosmetpantotenate, was being tested against placebo in 84 patients with pantothenate kinase-associated neurodegeneration , a rare, genetic and life-threatening disorder."We have realized that this is a failed study with no difference to placebo," Chief Executive Officer Eric Dube said.
The latest setback for Retrophin comes after the company settled all outstanding disputes with founder and former CEO Martin Shkreli, who was ousted in 2014 and later convicted for conspiring to manipulate Retrophin's stock price.Shares of the San Diego, California-based company fell as much as 32per cent to US$11.84 in morning trade, hitting their lowest level in nearly five years, after fosmetpantotenate failed both primary and secondary goals of the study.
PKAN, which can lead to movement disorders and visual impairment, is estimated to affect up to 5,000 people worldwide, Retrophin said. There is currently no approved treatment for the condition, according to Retrophin. The late-stage study analyzed fosmetpantotenate using a scale to measure improvement in daily activity in patients called the PKAN-ADL scale through a period of 24 weeks.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: thenewpaper - 🏆 7. / 63 Read more »